Stifel Financial Corp Equillium, Inc. Transaction History

Stifel Financial Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.73 - $3.0 $7,386 - $30,357	10,119 New	10,119 $23,000
Q3 2020 Nov 16, 2020	SELL	$2.78 - $26.5 $118,480 - $1.13 Million	-42,619 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$2.34 - $3.53 $10,597 - $15,987	4,529 Added 11.89%	42,619 $126,000
Q4 2019 Feb 13, 2020	BUY	$3.0 - $5.0 $42,000 - $70,000	14,000 Added 58.12%	38,090 $128,000
Q3 2019 Nov 13, 2019	BUY	$3.31 - $5.6 $79,737 - $134,904	24,090 New	24,090 $91,000

11.3M

Ticker EQ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,352,100
Market Cap $25.8M
Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.